News

Carbios inks €7m collaboration
Enlarge image

FundingFrance

Carbios inks €7m collaboration

15.04.2013 - French green plastics company Carbios has secured exclusive patent rights from a collaboration with the National Institute for Agricultural Research.

The five-year collaboration of Carbios (Clermon-Ferrant) and INRA (Paris) at the Toulouse White Biotechnology (TWB) research centre is part of the €22m THANAPLAST™ private-public consortium on plastics, comprising the CNRS, INRA, the Université de Poitiers, Deinove, the Barbier Group, and the Limagrain Group.

 The Carbios-INRA project will focus on the development of bioprocesses for recovering plastic waste and producing economically competitive bio-based polymers. The interdisciplinary collaboration will include R&D staff from TWB, the 3BCar Carnot Institute and two INRA groups. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.

 Carbios is developing solutions for transforming the global supply of over 100 million tons of plastic waste into a novel, high-quality, renewable raw material for the plastics industry. The company offers a viable economic alternative to the depletion of agricultural resources and the rarefaction of fossil fuels.

Carbios CEO Jean-Claude Lumaret commented that "although Europe generates almost 25 million metric tons of plastic waste each year, only 20% of that is recycled. The recovery of such an important renewable resource is a key business issue. We are delighted to have signed this partnership agreement with LISBP and Micalis - two INRA R&D groups that are internationally renowned for their know-how and expertise in enzymatic bioprocesses. By combining our skills and resources, the resulting synergy will be an impressive driver for innovation and the development of breakthrough industrial bioprocesses".

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/carbios-inks-eur7m-collaboration.html

BusinessGermany

24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.

BusinessUK

20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.

BusinessEUGermanyUK

15.08.2014 Some of Europe’s biggest pharma companies are competing in a bidding war for US biotech Intermune Inc., Bloomberg reports, citing insider reports as the source.

ResearchEUGermanyUK

13.08.2014 The Ebola epidemic is still raging on in West Africa and thus far there is

neither vaccine nor cure for the viral disease. The only flickers of hope:

an experimental antibody serum and an early-stage vaccine.

BusinessFrance

11.08.2014 Will Sanofi succeed where Pfizer failed? The French pharmaceutical company has taken on the commercialisation of Mannkind Corporation’s inhaled insulin product Afrezza.

ResearchSwedenGermany

08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.

ResearchSwitzerlandDenmark

06.08.2014 Roche is re-expanding its involvement in RNAi technologies. The Swiss pharmaceutical company will pay up to €335m for the acquisition of the Danish company Santaris Pharma A/S.

ResearchUKSwitzerland

03.08.2014 In its efforts to become the leading country in genetic research, the UK has attracted investments worth more than £300m (€376m) to map 100,000 human genomes by 2017.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.85 EUR5.65%
  • CYTOS0.26 CHF4.00%
  • PAION2.48 EUR2.06%

FLOP

  • 4SC1.25 EUR-2.34%
  • FORMYCON6.75 EUR-1.75%
  • VITA 343.75 EUR-1.57%

TOP

  • SANTHERA83.50 CHF27.5%
  • BB BIOTECH140.45 EUR6.3%
  • HBM86.00 CHF3.7%

FLOP

  • MOLOGEN7.85 EUR-17.4%
  • WILEX2.36 EUR-15.7%
  • MEDIGENE4.48 EUR-12.5%

TOP

  • SANTHERA83.50 CHF3695.5%
  • CO.DON2.61 EUR226.2%
  • PAION2.48 EUR185.1%

FLOP

  • CYTOS0.26 CHF-93.5%
  • MEDIGENE4.48 EUR-67.4%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 27.08.2014